reported that PARP inhibitors enhanced the efficacy of CD70‐targeted CAR‐T therapy via activation of the cGAS‐STING signalling cascade in tumour cells, resulting in elevated CXCL10 and CCL5 expression and promoting CAR‐T cell infiltration and cytotoxicity. The gene discussed is CD70; the disease is neoplasm.